Johnson & Johnson (JNJ)
Johnson & Johnson's stock is under pressure due to ongoing baby powder and Tylenol lawsuits, despite positive developments in robotics and drug research. Recent analyst upgrades suggest potential for upward movement.
About Johnson & Johnson
Johnson & Johnson is a multinational healthcare company.
Johnson & Johnson uses the ticker $JNJ for trading. Listed in the Stocks category within the Healthcare sectors.
Insights
- Johnson & Johnson (JNJ) engagements hit 1.3M which is 144% higher than it's daily average.
- Johnson & Johnson (JNJ) social dominance is up 417.16% from the previous week.
- Johnson & Johnson (JNJ) sentiment is up 26.47% from the previous week.
- Johnson & Johnson (JNJ) engagements is up 68.78% from the previous week.
- Johnson & Johnson (JNJ) posts created is up 210.17% from the previous month.
- Johnson & Johnson Price hit a 52-Week high of $245.60 for the hour
- Johnson & Johnson Price hit an all time of $245.60 for the hour
Price: $242.80
Price 24-Hour Time-Series Raw Data
Despite hitting a 52-week high, JNJ's stock is under pressure due to ongoing lawsuits concerning baby powder and Tylenol, which overshadow positive developments in robotics and drug research. Recent analyst upgrades suggest potential for upward movement.
24-Hour: -0.26% 7-Day: 1.58% 30-Day: 11.04%
1-Year High: $244.60 on 2026-02-12
1-Year Low: $146.40 on 2025-05-14
AltRank: [---]
AltRank 24-Hour Time-Series Raw Data
Johnson & Johnson (JNJ) is currently AltRank #124 based on combined combined social and market metrics
Daily Average: [---]
[--] Week: [---] +82
[--] Month: [---] [----]
[--] Months: [---] [----]
[--] Year: [---] [---]
1-Year High: [-----] on 2025-03-16
1-Year Low: [--] on 2025-04-17
Galaxy Score: [-----]
Galaxy Score 24-Hour Time-Series Raw Data
Current Value: [-----]
Daily Average: [--]
[--] Week: [--] [---]
[--] Month: [--] [---]
[--] Months: [--] [---]
[--] Year: [--] +14
1-Year High: [--] on 2025-11-10
1-Year Low: [--] on 2026-02-09
Engagements: [---------] (24h)
Engagements 24-Hour Time-Series Raw Data
Current Value: [---------]
Daily Average: [-------]
[--] Week: [---------] +69%
[--] Month: [---------] +24%
[--] Months: [----------] -9.30%
[--] Year: [-----------] -9.50%
1-Year High: [---------] on 2025-06-10
1-Year Low: [------] on 2026-02-01
Engagements by network (24h): News: [---] YouTube: [------] TikTok: [---------] Reddit: [---] X: [------] Instagram: [-----]
Mentions: [-----] (24h)
Mentions 24-Hour Time-Series Raw Data
Current Value: [-----]
Daily Average: [-----]
[--] Week: [-----] +3.80%
[--] Month: [------] +158%
[--] Months: [-------] +187%
[--] Year: [-------] +134%
1-Year High: [-----] on 2025-12-15
1-Year Low: [---] on 2025-06-08
Mentions by network (24h): News: [--] YouTube: [---] TikTok: [--] Reddit: [--] X: [---] Instagram: [--]
Creators: [---] (24h)
Creators 24-Hour Time-Series Raw Data
[---] unique social accounts have posts mentioning Johnson & Johnson (JNJ) in the last [--] hours which is up 21% from [---] in the previous [--] hours
Daily Average: [---]
[--] Week: [-----] -3.40%
[--] Month: [-----] +74%
[--] Months: [------] +121%
[--] Year: [------] +334%
1-Year High: [-----] on 2025-10-29
1-Year Low: [---] on 2025-06-08
The most influential creators that mention Johnson & Johnson in the last [--] hours
| Creator | Rank | Followers | Posts | Engagements |
|---|---|---|---|---|
| @tunemusicalmoments | [--] | [---------] | [--] | [------] |
| @salmaogs | [--] | [------] | [--] | [-----] |
| @Andre_AGTC | [--] | [-----] | [--] | [-----] |
| @ppatour | [--] | [-------] | [--] | [-----] |
| @eye7chaudharyeyecentre | [--] | [---------] | [--] | [-----] |
| @nerfcedxvi | [--] | [-------] | [--] | [-----] |
| @aljazeera | [--] | [----------] | [--] | [-----] |
| @AreOhEssEyeEe | [--] | [-------] | [--] | [-----] |
| @user7111965156681 | [--] | [--] | [-----] | |
| @Rich69Johnson | [--] | [---] | [--] | [-----] |
Sentiment: 20%
Sentiment 24-Hour Time-Series Raw Data
Current Value: 20%
Daily Average: 77%
[--] Week: 86% +18%
[--] Month: 75% -7%
[--] Months: 75% -13%
[--] Year: 75% -3%
1-Year High: 99% on 2025-06-04
1-Year Low: 6% on 2025-12-15
Most Supportive Themes:
- Robotics Development: (1%) Johnson & Johnson is advancing its healthcare robotics development using NVIDIA's Isaac platform.
- Oral Drug Development: (1%) Johnson & Johnson is developing oral drugs, with positive results from the Phase 2b ANTHEM-UC study.
Most Critical Themes:
- Talc Baby Powder Lawsuits: (30%) Johnson & Johnson faces renewed scrutiny and lawsuits over its baby powder products, with allegations of cancer links.
- Tylenol Autism Risk Lawsuit: (30%) Texas AG is suing Johnson & Johnson and Kenvue, alleging deceptive marketing of Tylenol and concealment of autism risks in unborn children.
Social Dominance: 0.085%
Social Dominance 24-Hour Time-Series Raw Data
Current Value: 0.085%
Daily Average: 0.189%
[--] Week: 0.313% +0.253%
[--] Month: 0.138% +0.01%
[--] Months: 0.138% -0.133%
[--] Year: 0.138% -0.047%
1-Year High: 1% on 2025-12-15
1-Year Low: 0.082% on 2026-02-15
Market Dominance: 0.666%
Market Dominance 24-Hour Time-Series Raw Data
Current Value: 0.666%
Daily Average: 1%
1-Year High: 0.772% on 2025-03-12
1-Year Low: 0.484% on 2025-06-30
Market Cap: $584,882,471,767
Market Cap 24-Hour Time-Series Raw Data
Current Value: $584,882,471,767
Daily Average: $432,622,051,849
[--] Week: $583,677,522,299 +1.40%
[--] Month: $583,677,522,299 +11%
[--] Months: $583,677,522,299 +35%
[--] Year: $583,677,522,299 +55%
1-Year High: $589,340,784,799 on 2026-02-12
1-Year Low: $352,152,885,114 on 2025-05-14
Top Johnson & Johnson Social Posts
Top posts by engagements in the last [--] hours
Showing a maximum of [--] top social posts without a LunarCrush subscription.
"$JNJ . FDA approves RYBREVANT FASPRO as the only EGFR-targeted therapy that can be administered once a month (243.45) HORSHAM Pa. Feb. [--] [----] /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced the U.S. Food and Drug Administration (FDA) has approved a new simplified monthly dosing schedule* for RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj). When administered in combination with oral LAZCLUZE (lazertinib) for the first-line treatment of epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer (NSCLC) monthly dosing delivers consistent outcomes"
X Link @MartyChargin 2026-02-17T13:05Z 49.8K followers, [----] engagements
"$JNJ FDA approves RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj) as the only EGFR-targeted therapy that can be administered once a month https://www.stocktitan.net/news/JNJ/fda-approves-rybrevant-fasprotm-amivantamab-and-hyaluronidase-lpuj-9ri8x2rz05hy.html https://www.stocktitan.net/news/JNJ/fda-approves-rybrevant-fasprotm-amivantamab-and-hyaluronidase-lpuj-9ri8x2rz05hy.html"
X Link @Lycanbull 2026-02-17T13:02Z [----] followers, [---] engagements
"Open Interest Update (Check original tweet for contract info) $CLS 1169/1269 ✅ $COIN 1054/1113 ✅ $EPD 16481/18839 ✅ $IBM 3678/4311 ✅ $JNJ 2249/2445 ✅ $NEM 5846/6055 ✅ $TSM 1751/1766 ✅ $UWMC 3044/3112 ✅ The check mark indicates that the whale held more than half of their position. 2/15 Notable Flow $CLS [---] C 03/20/2026 $2.9M 23.45avg $COIN [---] C 01/15/2027 $2.8M 25.20avg 40% OTM $EPD [--] C 01/15/2027 $1.1M .61avg 13% OTM $IBM [---] C 03/20/2026 $2.6M 6.23avg $JNJ [---] C 03/13/2026 $1.1M 4.72avg $NEM [---] C 07/17/2026 $6.3M 10.44avg 15% OTM (ER in 4D) $TSM 2/15 Notable Flow $CLS [---] C 03/20/2026"
X Link @salmaogs 2026-02-17T12:47Z 40.9K followers, [----] engagements
"You've been FUD'ing out on $CMPS for the past [--] hours. Why don't you disclose your other positions because you were no where to be found on this topic prior. @richtrades100 even if the delta had been larger this drug 'procedure' would be commercially constrained. people really don't appreciate how difficult it was for $jnj to launch spravato - a small biotech like $cmps will not be able to gain much of the market with their current product profile. @richtrades100 even if the delta had been larger this drug 'procedure' would be commercially constrained. people really don't appreciate how"
X Link @B__Digs 2026-02-17T12:26Z [---] followers, [---] engagements
Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing